Coya Therapeutics (COYA) FCF Margin (2023 - 2026)
Coya Therapeutics (COYA) posted FCF Margin of 2472.07% for Q1 2026, down 9620.12% sequentially from 25.43% in Q4 2025, and down 137535.0% YoY from N/an in Q1 2025.
Coya Therapeutics (COYA) FCF Margin (2023 - 2026) Analysis & Trends
Coya Therapeutics has reported FCF Margin for 4 years, with the latest figure at 2472.07% in Q1 2026.
- Quarterly FCF Margin fell 137535.0% year-over-year to 2472.07% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 177.85% (up 23633.0% YoY) and the FY2025 annual result came in at 135.16%, up 15434.0% from the prior year.
- FCF Margin declined to 2472.07% in Q1 2026 per COYA's latest filing, from 25.43% in the prior quarter.
- Over five years, FCF Margin peaked at 1691.82% in Q1 2024 and troughed at 123451.18% in Q4 2024.
- A 4-year average of 14342.72% and a median of 133.23% in 2024 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2024 and 2025: FCF Margin tumbled 12341384 bps in 2024, then soared 12342575 bps in 2025.
- Over 4 years, FCF Margin stood at 37.34% in 2023, then tumbled by 330535 bps to 123451.18% in 2024, then soared by 100 bps to 25.43% in 2025, then tumbled by 9620 bps to 2472.07% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 2472.07%, 25.43%, and 31.72% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 70.82% |
| 10 | Coya Therapeutics | 113.53 Mn | 70.33 Mn | - | -3,026.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,026.08% |
| Mar 31, 2026 | -2,472.07% |
| Dec 31, 2025 | -25.43% |
| Sep 30, 2025 | -31.72% |
| Jun 30, 2025 | -3,528.56% |
| Mar 31, 2025 | -1,096.72% |
| Dec 31, 2024 | -123,451.18% |
| Jun 30, 2024 | -133.23% |
| Mar 31, 2024 | 1,691.82% |
| Dec 31, 2023 | -37.34% |